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Vaginitis is a very common gynecological problem in women of all age groups.
There are three types of infectious vaginitis: candidiasis, trichomoniasis, and bacterial
vaginosis (1, 2). Vaginitis can be caused by single or mixed vaginal infections (2–4). Ap-
proximately 30% of all cases of vaginitis are caused by simultaneous infections with at
least two or more pathogens (e.g. bacterial vaginosis in patients of vulvovaginal candi-
diasis) (5). Vaginal infections can be diagnosed by clinical examinations, pH measure-
ment and microscopic examination of vaginal discharge (1, 6). The pH of vaginal secre-
tion is elevated (> 4.5) in case of bacterial vaginosis and trichomoniasis (1). Combination
therapy may provide immediate and effective treatment for vaginal infections, irrespec-
tive of single or multiple types or even when the diagnosis is not precisely accurate (5).
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An acid buffering bioadhesive vaginal (ABBV) gel was
developed for the treatment of mixed vaginal infections.
Different bioadhesive polymers were evaluated on the
basis of their bioadhesive strength, stability and drug re-
lease properties. Bioadhesion and release studies showed
that guar gum, xanthan gum and hydroxypropyl methyl-
celullose K4M formed a good combination of bioadhesi-
ve polymers to develop the ABBV gel. Monosodium ci-
trate was used as an acid buffering agent to provide aci-
dic pH (4.4). The drugs clotrimazole (antifungal) and me-
tronidazole (antiprotozoal as well as antibacterial) were
used in the formulation along with Lactobacillus spores to
treat mixed vaginal infections. The ex vivo retention study
showed that the bioadhesive polymers hold the gel for
12–13 hours inside the vaginal tube. Results of the in vi-
tro antimicrobial study indicated that the ABBV gel had
better antimicrobial action than the commercial intrava-
ginal drug delivery systems and retention was prolonged
in an ex vivo retention experiment.
Keywords: acid buffering gel, vaginal bioadhesion, bio-
adhesive polymers, mixed vaginal infections
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The conventional formulations of vaginal drug delivery systems (VDDS) are associ-
ated with poor retention due to the self-cleansing action of vaginal tract, leading to poor
compliance (7). To overcome this problem, bioadhesive polymers are added to VDDS.
Bioadhesive polymers can hold the drug delivery systems in the vaginal tube by inter-
acting with vaginal mucosa and thereby increase patient compliance as well of delivery
system efficiency (8, 9).
Bioadhesive polymers like hydroxypropyl methylcellulose (HPMC), sodium carbo-
xymethyl cellulose (Na-CMC), xanthan gum, guar gum, sodium alginate show good sta-
bility in the wide range of pH 3–10 and are hence good candidates for vaginal drug de-
livery systems at pH 3.8–4.5. The drugs clotrimazole and metronidazole were selected
because they are broad-spectrum antimicrobial agents (10, 11) and spores of Lactobacilli




Metronidazole, clotrimazole and Lactobacillus acidophilus spores were obtained as
gift samples from Lark laboratories (India). Commercially available intravaginal formu-
lations (Candid V – 2% gel of clotrimazole in inactive gel base produced by Glenmark
Pharmaceutical Ltd. India and Canesten1 – 10% cream of clotrimazole in inactive cream
base produced by Bayer, Germany) were purchased from the market. Bioadhesive poly-
mers and monosodium citrate were obtained as gift samples from Ranbaxy (India) and
Oscar Laboratories (India), respectively. Other chemicals used were of LR grade and im-
mediately used after procurement. TAXT2i/Texture analyzer of Stable Microsystems
was used to measure in vitro bioadhesion. The gel pH was measured using a surface pH
electrode Orion 9135AP model, Aqua Pro flat surface pH (Thermo Electron Corporation,
UK).
Preparation of simulated vaginal fluid
Simulated vaginal fluid (SVF) was prepared by dissolving sodium chloride, potas-
sium hydroxide, calcium hydroxide, bovine serum albumin, lactic acid, acetic acid, glyc-
erol, urea and glucose in water; pH was adjusted to 4.2 by using 1 mol L–1 HCl (13).
Gels
Metronidazole was dissolved in water followed by dispersing the polymers. Carbo-
pol and polycarbophil gel was prepared by neutralization with sodium hydroxide. Gels
of cellulose derivatives and natural polymers (gums, alginate) were prepared by over-
night soaking of the polymers for complete hydration. Clotrimazole and methylparaben
were dispersed in the swelled gel under stirring. These gel formulations were developed
to study the effect of individual gelling polymers on the drug release behavior. Gels of
individual polymers were named GA, GB, GC, GD, GE, GF, GG, and GH and their com-
positions are given in Table I.
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Combination gels
In combination gels, prolonged release polymers as well as fast eroding/swelling
polymers were used and their effects on drug release and gel properties were optimized.
Compositions of combination gels are given in Table II.
Modified dissolution apparatus
The USP dissolution apparatus II (14) was modified for release studies of gels. A cir-
cular, 2.38-mm mesh stainless steel net of 8.0 cm diameter was placed at the bottom of
the dissolution vessel. A stainless steel plate of 5.5 cm internal diameter and 5 mm height,
with 5 g gel, was placed on the wire net (15). The paddle was set at the height of 2.5 cm
from the gel surface. The dissolution medium (900 mL) for gels and combination gels
was 0.5% (m/V) solution of sodium lauryl sulphate in water. For acid buffering gel, the
dissolution medium was 900 mL of simulated vaginal fluid with 0.5% (m/V) sodium la-
uryl sulphate. Paddle speed was set to 50 rpm and the temperature was maintained at
37 ± 0.5 °C. The sampling volume was replaced by fresh dissolution medium.
In vitro adhesion tests
The in vitro mucoadhesive properties of combination gels were assessed on bovine
vaginal mucosa, using a TAXT2i Texture Analyzer. The test parameters were: pretest
speed 0.5 mm s–1, test speed 0.1 mm s–1, contact time 3.0 min, preload 1 N, load cell 500
N, diameter of upper probe 36 mm. The experiment was carried out at room temperature.
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Table I. Composition of gels
Ingredient
Gel formulation (%, m/m)
GA GB GC GD GE GF GG GH
Metronidazole 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75
Clotrimazole 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Na-CMC 4.0 – – – – – – –
HPMC-K15M – 4.0 – – – – – –
HPMC-K100M – – 4.0 – – – – –
Na-alginate – – – 4.0 – – – –
Guar gum – – – – 4.0 – – –
Xanthan gum – – – – – 5.0 – –
Carbopol-971 – – – – – – 1.0 –
Polycarbophil – – – – – – – 1.0
NaOH – – – – – – 0.4 0.4
Methylparaben 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
q.s. – quantum satis
The vaginal mucosal tissue was cleaned, washed and stored at –20 °C. The stored
vaginal tissue was treated with 0.1% (m/V) sodium azide and allowed to reach normal
temperature before commencement of the experiment. Preserved, cleaned and thawed
vaginal mucosa was incised longitudinally just before the experiment. Vaginal tissue was
mounted on the platform below the texture analyzer probe. A cellophane membrane, equi-
librated with SVF at room temperature for 24 hours was tied to the upper probe. Surface
of vaginal mucosa was moisturized with simulated vaginal fluid and gel was applied.
The test was run after completing the pre-test requirements.
Development of an acid buffering prolonged release bioadhesive gel
Composition of ABBV gel is given in Table III. The ingredients metronidazole, mono-
sodium citrate, Lactobacilli, methylparaben and glycerin were dispersed in water. The po-
lymers were dispersed in this solution under stirring and the composition was allowed
to swell for 24 h. Finally, clotrimazole was mixed under stirring into the swollen gel.
Apparatus for ex vivo retention studies
The apparatus for ex vivo retention studies consisted of a glass cell, peristaltic pump,
beaker, thermometer, magnetic stirrer and vaginal mucosa. The cell was a glass tube
(length 11.0 cm, external diameter 5.0 cm) with openings at both ends; the diameter of
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Table II. Composition of combination gels
Ingredient
Gel formulations (%, m/m)
G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14
Metronidazole 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75
Clotrimazole 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Guar gum 2 2 2 – – – 2 – 2 – 1.5 1.5 – –
Na-CMC 2 – – – 1.5 – – – – – – – – –
HPMC-K15M – 2 – 2 – – – – – – – – – –
HPMC-K4M – – 2 – – 2 – – 1 1 0.5 0.5 0.5 0.5
Na-alginate – – – 2 2 2 – 2 – 2 – – 1.5 1.5
Xanthan gum – – – – – – 2 2 1 1 – – – –
Carbopol – – – – – – – – – – 0.5 – 0.5 –
Polycarbophil – – – – – – – – – – – 0.5 – 0.5
NaOH – – – – – – – – – – 0.2 0.2 0.2 0.2
Glycerin 30 30 30 30 30 30 30 30 30 30 30 30 30 30
Methylparaben 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.
q.s. – quantum satis
the upper opening was 2.4 cm and 1.0 cm of the lower opening. The edges of upper and
lower openings were molded to aid in tying the tissue properly. Two small side arms
were present at both ends of the glass cell, placed 4.5 cm apart from each other; the
lower side arm was used as inlet and the upper as outlet. Distilled water was circulated
through these side arms into the glass cell by a pump. A peristaltic pump was used to
circulate the SVF through the vaginal tract. Temperature of SVF and the circulating liq-
uid was maintained at 37 °C. Apparatus for ex vivo studies was a modified version of the
Setnikar and Fantelli apparatus (16).
Ex vivo retention measurement
An intact tubular piece of processed and preserved bovine vaginal mucosa was cut
to proper size and vertically mounted in a glass cell. The ends of the vaginal mucosal
tube were averted on the tapering of the upper and lower ends of the glass cell and
crimped using rubber bands so that both ends of the vaginal tube remained open. Dis-
tilled water (37 °C) was circulated through the cell using a pump. This circulating water
maintained the temperature, equivalent to body temperature, and kept the tissue moist
from the outside. The 5 g acid buffering bioadhesive gel/Canesten-1 cream was inserted
into the vaginal tube using an applicator. After putting the formulation inside the vagi-
nal tube, a preload time of five minutes was allowed so that the formulation got adhered
to the vaginal walls. Simulated vaginal fluid was allowed to fall dropwise into the verti-
cally suspended vaginal tube holding the formulation, using a peristaltic pump. The
rate of simulated vaginal fluid was maintained at 3 mL h–1 and expulsion of the formu-
lation was recorded from the lower end of the cell.
pH determination
The pH of the acid buffering bioadhesive gel was measured by putting the tip of
surface electrode to the gel surface and the results were taken as a mean of three deter-
minations.
411
F. Jalees Ahmad et al.: Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections,
Acta Pharm. 58 (2008) 407–419.





Guar gum 1.5 g





Water q.s. 100 g
q.s. – quantum satis
Measurement of gel spreadability
Concentric circles of different radii were drawn on graph paper and a glass plate was
fixed onto it. Gel (5.0 g) was transferred to the centre of the lower plate and spread over
an area of 2 cm diameter. The glass plate of 100 ± 5 g was placed gently on the gel and the
spread diameter was recorded after 1 minute; subsequent glass plates were added and
the spread diameter was recorded after 1 minute of each addition. Results were presen-
ted as the spreading area being a function of the applied mass (17). Spreadability of the
developed formulation was compared with the commercial formulation Candid-V gel.
Antifungal and antimicrobial studies
The in vitro antimicrobial studies were carried out by the cup plate method using
Candida albicans and Escherichia coli microorganisms.
Sterilized Sabouraud’s agar/nutrient agar medium (25 mL) was poured into steril-
ized Petri plates (diameter 15 cm) under laminar air flow and allowed to solidify. The 0.4
mL aqueous suspension of Candida albicans/Escherichia coli was spread uniformly on so-
lidified Sabouraud’s agar/nutrient agar medium. The cups were cut and formulations
were filled into different cups using sterilized syringes, under laminar air flow. Plates
were covered with lids and incubated in BOD at 32 °C for 40 hours. The zones of inhibi-
tion were measured after 40 hours.
RESULTS AND DISCUSSION
Gels and combination gels
Gels with particular polymers were prepared to study the effect of each polymer on
the release profile (Table IV). The gels GA (Na-CMC, 4%), GB (HPMC-K15M, 4%), GC
(HPMC-K100M, 4%), GF (xanthan gum, 5%), GG (Carbopol-971, 1%), and GH (polycar-
bophil, 1%) released more than 95% of metronidazole within 3 h. All these gels except
GA released 100% of clotrimazole within 4 h. In gels GA, GB, GC, GF, GG and GH, the
dissolution or erosion of the gelling polymer was rapid and most of the gel got dissol-
ved within 4 h. Sodium alginate (GD) and guar gum (GE) gels showed integrity beyond
7 h and did not dissolve completely even after 7 h. In gels with particular polymers, the
release of metronidazole was faster compared to clotrimazole since metronidazole was in so-
lution form in the gel matrix whereas clotrimazole was suspended in the hydrophilic gel
matrix. Guar gum and sodium alginate were selected as a stable base forming material
in combination with other fast dissolving polymers so that the integrity of the gel could
be maintained up to 5 h.
Combination gels, namely gels with a combination of polymers showed prolonged
release dissolution profiles (Table V). The prolonged integrity and release from these
gels (gel-G1 to gel-G14, gels with different polymer ratios) were achieved by using guar
gum or sodium alginate as rigid gel structure forming agents. As the erosion/dissolu-
tion of guar gum and sodium alginate gels is very slow, fast dissolving/eroding poly-
mers were used in combination with these slow eroding polymers in different composi-
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GA 0 0 0 GE 0 – 0
30 78.0 24.4 60 – 19.5
60 90.0 36.6 120 – 28.6
120 95.3 73.9 180 – 34.5
240 99.0 83.5 240 – 43.0
420 99.0 94.3 300 – 53.3
GB 0 0 0 GF 0 0 0
30 72.0 46.0 10 55.6 20.0
60 96.0 94.0 30 63.9 25.6
120 99.0 95.2 90 76.0 31.9
240 99.0 104.2 210 88.2 70.4
420 99.0 104.0 330 92.4 108.1
GC 0 0 0 GG 0 0 0
30 67.2 34.1 30 86.4 80.7
60 81.6 57.0 60 96.0 101.8
120 98.7 82.4 120 98.7 105.4
240 98.7 100 240 100.1 105.4
GD 0 0 0 GH 0 0 0
60 31.2 25.9 30 76.8 53.2
120 41.1 38.6 60 96.0 83.9
180 46.6 45.9 120 96.0 106.4
240 53.8 54.6 240 100.8 106.4
300 62.6 65.8










Metronidazole Clotrimazole Metronidazole Clotrimazole
G1 0 0 0 G8 0 0 0
30 52.8 22.6 10 6.2 15.5
60 67.2 32.4 30 6.2 19.7
120 91.2 54.9 90 7.9 21.1
240 98.7 89.1 210 21.1 42.4
360 100.0 100.9 330 32.7 51.8
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G2 0 0 0 G9 0 0 0
10 32.2 27.7 10 32.1 31.9
30 37.9 37.8 30 36.8 35.7
90 59.9 70.0 90 51.8 53.1
210 76.1 86.8 210 79.6 77.2
330 95.8 100.4 330 99.2 100.9
G3 0 0 0 G10 0 0 0
10 28.7 21.1 10 10.3 14.8
30 36.8 23.5 30 21.1 15.4
90 55.3 53.9 90 35.2 38.2
210 63.4 75.9 210 65.8 73.8
330 77.3 103.9 330 84.0 107.4
G4 0 0 0 G11 0 0 0
10 33.3 34.7 10 25.2 23.5
30 50.7 39.2 30 24.4 25.3
90 61.1 71.7 90 41.8 28.8
210 73.8 88.2 210 57.5 36.8
330 85.3 96.6 330 65.8 37.5
G5 0 0 0 G12 0 0 0
10 33.3 31.6 10 18.6 29.1
30 36.8 39.9 30 30.2 30.9
90 52.8 67.9 90 46.7 35.7
210 66.8 87.5 210 67.4 43.1
330 70.3 90.6 330 71.6 44.8
G6 0 0 0 G13 0 0 0
10 33.3 33.6 10 21.9 22.5
30 39.1 40.3 30 28.5 26.0
90 61.1 69.3 90 42.6 27.7
210 80.7 101.8 210 58.3 32.6
330 93.4 106.0 330 67.7 41.1
G7 0 0 0 G14 0 0 0
10 3.7 16.2 10 25.2 23.2
30 4.5 28.1 30 29.4 30.2
90 7.9 29.5 90 60.0 49.7
210 17.8 33.3 210 69.1 58.1
330 24.4 42.9 330 80.7 64.8
tions to improve the release pattern of the drugs. To further retard the release of the wa-
ter-soluble drug metronidazole, the drug was mixed with ethyl cellulose (3%) using iso-
propyl alcohol as granulating agent. The release profile of gels G1 to G6 was prolonged
and almost similar, because the polymers used in these gels had almost identical disso-
lution behavior (HPMC and Na-CMC) and a strong structure forming property (guar gum
and sodium alginate) (G1 guar gum 2% + Na-CMC 2%, G2 guar gum 2% + HPMC-K15M
2%, G3 guar gum 2% + HPMC-K4M 2%, G4 Na-alginate 2% + HPMC-K15M 2%, G5
Na-alginate 2% + Na-CMC 1.5% and G6 Na-alginate 2% + HPMC-K4M 2%). The release
of the drug from gels G7 and G8 containing xanthan gum was more prolonged com-
pared to gels G1 to G6 (G7 xanthan gum 2% + guar gum 2% and G8 xanthan gum 2% +
Na-alginate 2%). As the erodability and swelling nature of xanthan gum are lower than
those of Na-CMC and HPMC, the release through gels containing xanthan gum was pro-
longed. In gels G9 and G10, the amount of structure forming agents (guar gum or
Na-alginate) was kept constant (2%) but the fast dissolving polymer (HPMC-K4M) was
used in combination, so that an aesthetic and desirable gel with good bioadhesive
strength could be achieved (G9 xanthan gum 1%, HPMC-K4M 1% + guar gum 2% and
G10 xanthan gum 1%, HPMC-K4M 1% + Na-alginate 2%). The release profile of gels G9
and G10 was more or less similar to gels G1 to G6. Physical incompatibility was obser-
ved in G11 to G14 (G7 xanthan gum 2% + guar gum 2% and G8 xanthan gum 2% +
Na-alginate 2%); the gels turned yellow when carbopol and polycarbophil were neutrali-
zed by sodium hydroxide in the presence of guar gum or sodium alginate. The release
profiles of these gels were much prolonged.
In vitro bioadhesion
The force required to detach the formulation from the surface of tissue was deter-
mined as the »peak value« in the resultant force-time plot (Fig. 1). The bioadhesive
strength of combination gel formulations is given in Fig. 2. The bioadhesive strength of
G9 formulation was found to be 0.524 N, pointing to good bioadhesion. Release profile
of G9 gel was prolonged and uniform for both drugs. The G9 formulation was selected
for the development of an acid buffering bioadhesive vaginal gel formulation.
415
F. Jalees Ahmad et al.: Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections,
























500 100 150 200 250 300 350 400
Fig. 1. Representative graph of the in vitro bioadhesion test.
Acid buffering bioadhesive vaginal gel
On the basis of its drug release profile and bioadhesive strength, the gel formulation
G9 was selected for the development of an acid buffering prolonged release bioadhesive
gel. Metronidazole, clotrimazole and Lactobacilli were used as a broad-spectrum combi-
nation. Monosodium citrate was used to maintain pH 4.4 of the acid buffering prolon-
ged release bioadhesive gel (18). Guar gum was used in the formulation to provide a
rigid gel and a prolonged releasing component. Xanthan gum and HPMC-K4M were
used to provide smoothness and better spreadability along with improved release proper-
ties. All of these bioadhesive polymers are stable over a wide range of pH (3–10). In the
ex vivo experiment, the ABBV gel retention time was up to 12–13 h. The developed
ABBV gel showed more resistance to viscosity changes due to SVF absorption and thus
showed better retention than the commercial vaginal gel/cream which started to leak
within 5–6 h. Besides, creams do not have the capacity to absorb and hold fluid since
bioadhesive gels do and leak out when the surface of the vaginal wall gets lubricated by
simulated vaginal fluid. Good spreadability of the semisolid formulation is required for
better action. Spreadability of the developed gel was found to be poor compared to com-
mercial gel (Candid-V gel) (Fig. 3). The reason for poor spreadability of acid buffering
gel was its high viscosity and the presence of the rigid gel forming agent, guar gum.
These parameters speak in favor of better bioadhesion and prolonged retention of the
gel. Almost 100% drug released from the ABBV gel, within 6 h while only 84% drug re-
leased from Candid-V gel in 6 h (Fig. 4). Physical appearance of the gel was evaluated
with naked eye. The gel was smooth, without any lumps and of uniform white color. No
color change/liquefication/separation were observed after six-month storage at 40 °C,
75% RH.
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Fig. 3. Spreadability study of the acid
buffering bioadhesive gel and Candid-V
gel.
Antimicrobial studies
The in vitro efficacy of the developed ABBV gel was compared with commercial
gel/cream formulations. Developed gel was found to be more effective in in vitro condi-
tions. The average zone of inhibition of the developed ABBV gel against Candida albicans
was 32.3 ± 0.6 mm compared to 25.3 ± 0.6 mm and 25.3 ± 0.6 mm of commercial formula-
tions Canesten-1 and Candid-V gel, respectively, indicating significantly higher efficacy
of ABBV gel (p > 0.001). Average zone of inhibition of the developed ABBV gel against
E. coli was 23.0 ± 0.0 mm compared to 21.0 ± 0.0 mm of Candid-V gel. From the results of
in vitro antimicrobial activity it is clear that the developed ABBV gel was more effective
than the tested commercial formulations.
CONCLUSIONS
An acid buffering bioadhesive vaginal gel was developed for the treatment of single
as well as mixed vaginal infections. The developed bioadhesive gel was found to have
prolonged ex vivo retention. The in vitro results of antimicrobial activity suggest that the
acid buffering bioadhesive gel was more efficacious than the commercial formulations
tested.
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Fig. 4. Cumulative percent
release profiles from com-
bined acid buffering bio-
adhesive gels and Candid-
-V gel (X ± SD, n = 3).
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S A @ E T A K
Razvoj i in vitro vrednovanje puferiranog bioadhezivnog
vaginalnog gela za mije{ane vaginalne infekcije
FARHAN JALEES AHMAD, MOHD AFTAB ALAM, ZEENAT IQBAL KHAN, ROOP KRISHEN KHAR i MUSHIR ALI
U radu je opisan razvoj puferiranog biodhezivnog vaginalnog (acid buffering bioadhe-
sive vaginal, ABBV) gela za terapiju mije{anih vaginalnih infekcija. Ispitani su razli~iti
bioadhezivni polimeri – procijenjena su njihova bioadhezivna svojstva, stabilnost i spo-
sobnost osloba|anja ljekovite tvari. Guar guma, ksantan guma i hidroksipropilmetilce-
luloza K4M tvore dobru kombinaciju za ABBV gel. Mononatrijev citrat upotrebljen je
kao puferiraju}a tvar koja omogu}ava blago kiseli pH (4,4), a kao ljekovite tvari upotreb-
ljeni su klotrimazol (antimikotik) i metronidazol (antiprotozoik i antibakterijsko sredstvo),
zajedno sa sporama Lactobacillus. Pripravci su upotrebljeni u terapiji mije{anih vaginal-
nih infekcija. Pokusi ex vivo pokazali su da se bioadhezivni gel zadr`ava u vagini 12–13
sati. Rezultati in vitro ispitivanja ukazuju na to da ABBV gel ima bolje antibakterijsko
djelovanje i dulje zadr`avanje od intravaginalnog sustava koji je dostupan na tr`i{tu.
Klju~ne rije~i: puferirani gel, vaginalna bioadhezija, bioadhezivni polimeri, mije{ane vaginalne infekcije
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